Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection

The Seventh Affiliated Hospital of Sun Yat-sen University100 enrolled

Overview

The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19. The main questions aims to answer are: * Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy. * Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19. * How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patients Participants will be asked to answer the question about: * the severity and duration of COVID-19 symptoms * the date of diagnosis of COVID-19 * the date of negative nucleic acid test * the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Tumor COVID-19

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022 to May 31. * COVID-19 was confirmed by antigen testing or nucleic acid testing. * Tumor was confirmed by pathology. * Patients received systemic antitumor therapy after infected with COVID-19. Exclusion Criteria: * COVID-19 was not confirmed by antigen testing or nucleic acid testing * Tumor was not confirmed by pathology * Patients did not receive systemic antitumor therapy * Patients died before receiving systemic antitumor therapy

Outcomes

Primary Outcomes

Incidence of adverse events after antitumor therapy

Incidence of adverse events after antitumor therapy, including hematologic toxicity,gastrointestinal adverse event, hepatobiliary adverse events, etc.

Time frame: 28 days after antitumor therapy

Re-infection of COVID-19

Antigen testing or nucleic acid testing positive for COVID-19

Time frame: 28 days after antitumor therapy

Secondary Outcomes

Clinical manifestations of COVID-19 in tumor patients

Symptoms and lab abnormality of COVID-19 in tumor patients

Time frame: Until nucleic acid testing turn negative